Clinical trial · Interventional
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
There Is No Place Like Home- A Pragmatic Effectiveness Trial of Technology-Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events. Receiving telemedicine and remote monitoring may help patients have better outcomes (such as fewer avoidable emergency room visits and hospitalizations, better quality of life, fewer symptoms, and fewer treatment delays) than patients who receive usual care.
Conditions
Conditions (45)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage IVA Gastric Cancer AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage IVB Gastric Cancer AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage IV Gastric Cancer AJCC v8 | — | UNRESOLVED |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Best Practice | Other | — | UNRESOLVED |
| Patient Monitoring | Procedure | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Arm I (standard of care)
- description
- Patients receive standard of care consisting of oncology care provided via telemedicine.
- interventionNames
- Other: Best Practice
- Other: Questionnaire Administration
- type
- EXPERIMENTAL
- label
- Arm II (standard of care, remote monitoring)
- description
- Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.
- interventionNames
- Other: Best Practice
- Procedure: Patient Monitoring
- Other: Questionnaire Administration
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults (≥ 18 years) * English- and Spanish-fluent participants with thoracic and/or gastrointestinal cancers who are scheduled to initiate or continue outpatient chemotherapy at either MDACC (Texas Medical Center campus and any Houston-area location) or MDACC oncology clinic at Lyndon B Johnson (LBJ) hospital * Their adult (≥18 years) patient-identified or self-identified primary caregivers (MDACC only) * Participants on combination chemotherapy and immunotherapy or combination chemotherapy and biologic will also be eligible for inclusion. * Participants may participate if they do not have a caregiver, or if their caregiver declines participation; however, caregivers of MDACC participants may participate only if the participant consents. Exclusion Criteria: * Participants who are receiving investigational new drug treatments or concurrently enrolled in a phase 1 clinical trial will be excluded due to the associated structured reporting and regulatory requirements. * Participants with a requirement for inpatient infusion (i.e. CAR-T cell therapy), living in institutional settings (i.e. prison, nursing homes), with a history of dementia, physical disability or neurological deficits that prohibit ability to report symptom burden will also be excluded.
References
Publications (1)
- DERIVEDOffodile AC 2nd, Delgado D, Lin YL, Geyen D, Miller CJ, Jain S, Finder JP, Shete S, Fossella FV, Overman MJ, Peterson SK. Integration of Remote Symptom and Biometric Monitoring Into the Care of Adult Patients With Cancer Receiving Chemotherapy-A Decentralized Feasibility Pilot Study. JCO Oncol Pract. 2023 Jun;19(6):e811-e821. doi: 10.1200/OP.22.00676. Epub 2023 Feb 23. PMID 36821818